Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140452
Status:
COMPLETED
Last Update Posted:
2007-11-21
First Post:
2005-08-31
Brief Title:
Phase II Study Using Thalidomide for the Treatment of ALS
Sponsor:
Dartmouth-Hitchcock Medical Center
Organization:
Dartmouth-Hitchcock Medical Center
Study Overview
Official Title:
Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The use of Thalidomide in patients with ALS who have disease progression
Detailed Description:
Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of disease progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None